Manufacturing Advances Key to Therapy Breakthroughs

Digital manufacturing must lead the next phase of cell and gene therapy scale up. The UK’s cell and gene therapy sector is currently hitting a “scalability ceiling.” While the region has been incredibly successful at moving therapies through Phase I and II trials, the transition to late-stage clinical and commercial manufacturing reveals deep-seated bottlenecks that threaten progress. The most prominent bottleneck is manual dependency and process fragmentation. Too many processes are still “open” and heavily reliant on human intervention. In autologous therapies, where the patient is the starting material, every batch is a unique production run. Analogue record-keeping and manual entry protocols create a massive “burden of proof” for Quality Assurance (QA). When scaling to hundreds or thousands of patients, the sheer volume of paper documentation becomes a physical and regulatory liability, leading to a “batch release lag” that can keep life-saving treatments sitting in a freezer instead of reaching patients.

Furthermore, the UK faces a facility utilisation crisis. High-grade cleanroom space is expensive and finite. As many current processes are manual and open, they require high-level environments to mitigate contamination risks. This limits the number of batches that can be produced simultaneously. Without moving toward closed, automated, and digitally orchestrated systems, the industry cannot achieve the “parallel manufacturing” necessary to lower costs and increase throughput. Finally, the talent gap remains a significant hurdle. The sector is not just lacking scientists, it is lacking “bioprocessing engineers” and digital-native operators who understand both the biology of the cell and the logic of the digital systems required to manage them.

At Autolomous, the view is that digitalisation serves as the foundational infrastructure for modern medicine. Implementing GMP-aligned digital platforms such as autoloMATE can serve three vital functions. The first is reducing batch failure, as human error remains the leading cause of batch deviations. Digital platforms like autoloMATE enforce “right-first-time” manufacturing by providing digital work instructions and real-time validation. This prevents an operator from using an expired reagent or skipping a critical incubation step. If a deviation occurs, the system flags it immediately, allowing for proactive intervention rather than post-hoc discovery.

The second function is improving data integrity. In the eyes of a regulator, if it isn’t documented, it didn’t happen. Paper records are prone to loss, transcription errors, and “data silos.” A digital platform ensures data provenance, creating an immutable trail of who did what, when, and with which materials. This “ledger” approach ensures that data is captured at the point of origin, eliminating the risks associated with manual back-filling of records. The third function is enhancing regulatory readiness. Digitalisation transforms the ‘Batch Record Review’ from a multi-week forensic investigation into a streamlined, exception-based process.

Through a long-standing partnership with the Cell and Gene Therapy Catapult, the tangible impact of transitioning from paper-based to GMP-compliant digital processes has been demonstrated. The partnership shows how digital manufacturing tools can inspire optimism by delivering measurable improvements. A 65% reduction in QA review time was achieved, making the sector more efficient and promising. Furthermore, a 40% reduction in manual data entry was realized. The automation of the flow of data from equipment directly into the electronic batch record (eBR) reduces the data entry error rate to close to zero. These are not just “efficiency gains”; they are fundamental shifts in the cost-of-goods (COGS) model. When labour burdens and the risk of failure are reduced, a direct path to commercial viability and broader patient access is created.

Investors today are becoming increasingly “manufacturing-savvy.” In the early days of cell and gene therapy, capital flowed toward scientific breakthroughs. Today, investors are looking for de-risked execution. Digital infrastructure is a primary indicator of a company’s maturity. An asset with a robust digital manufacturing strategy is viewed as more “investable” because it has a clear path to scale. It provides investors with transparency. If a company can show real-time data on process yields, batch success rates, and supply chain integrity, it builds a level of trust that paper-based companies simply cannot match.

Digital systems also facilitate comparability. As a therapy moves from Phase II to Phase III, or from one manufacturing site to another, digital records provide the “fingerprint” needed to prove to regulators (and investors) that the product remains the same. In a constrained capital environment, the companies that win will be those that can prove they can manufacture their therapy reliably, repeatedly, and at a sustainable margin. To secure its position as a global leader by 2030, the UK must prioritise three pillars. First, mandatory digitalisation and standardisation is required to move away from bespoke, “homegrown” manual systems. The UK government and industry bodies should incentivise the adoption of interoperable digital standards to ensure that different pieces of equipment and software can communicate.

Second, investment in “plug-and-play” infrastructure is imperative. The UK must expand its “Manufacturing Innovation Centres” to include virtualised training environments. This will allow the training of the next generation of operators faster and allow developers to “stress-test” their manufacturing processes in a virtual environment before a single cell is processed. Third, the UK should lead the way in creating pre-competitive data consortia. By sharing anonymised manufacturing data with the help of AI and privacy-preserving technologies, the nation can collectively identify why certain batches fail and how to optimise yields.